Pain, Pharmacokinetics
Conditions
Brief summary
The purpose of the study was to investigate the pharmacokinetics (i.e. the uptake, distribution and elimination from the body) of dermally applied buprenorphine during and after different application periods, i.e., a 96-hour and a 72-hour application of the Transtec (Registered Trademark) patch (release rate 35 micrograms per hour \[µg/hour\]). In the Transtec summary of product characteristics (prescribing information for the physician), the wearing time per patch is restricted to three days (72 hours) after which the patch has to be replaced. However, market experience has shown that the Transtec patches are sometimes worn for a period longer than three days, i.e. they sometimes happen to be only replaced every four days. There was currently no data available as how to evaluate this longer wearing period.
Interventions
DRUGTranstec 35 µg/hour transdermal patch
Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
Sponsors
Grünenthal GmbH
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Each participant will apply Transtec 35 µg/hour transdermal patch, once for 96 hours (Treatment A) and once for 72 hours (Treatment B) in randomized order. Between removal of the first patch and application of the second patch, there will be a washout period of at least 10 days.
Eligibility
Sex/Gender
MALE
Age
25 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male Caucasian volunteers, aged 25-45 years. * Body mass index (BMI) between 18 and 30 kilogram/squared meter (extremes included). * Good physical and mental health status (no current acute illness) determined on the basis of the medical history and a general clinical examination. * Systolic blood pressure between 90 millimeter mercury (mmHg) and 150 mmHg (extremes included). * Diastolic blood pressure between 45 mmHg and 90 mmHg (extremes included). * Pulse rate between 45 beats per minute (bpm) and 100 bpm (extremes included). * Electrocardiogram (12 lead) considered as normal by the investigator. * Results of laboratory tests within the normal ranges for the testing laboratory. The investigator may include a participant having values outside the accepted range if, in his/her opinion, these values are of no clinical relevance. The decision will be justified. * The participant has been informed using the informed consent approved by the local ethics committee. * The consent was obtained by participant's signature.
Exclusion criteria
* Diseases and functional disorders of the central nervous system (CNS), endocrinological system, gastrointestinal tract, hepatobiliary system, renal system, respiratory system or cardiovascular system including marked repolarization abnormality (e.g. suspicious or definite congenital long QT syndrome) or co-medication that is known to influence cardiac repolarization substantially. * History of seizures or at risk (i.e. head trauma, epilepsy in family anamnesis, unclear loss of consciousness). * Malignancy. * History of orthostatic hypotension. * Positive human immunodeficiency virus (HIV) 1/2-antibodies, hepatitis B surface (HBs) -antigen, hepatitis B core (HBc) -antibodies, hepatitis C virus (HCV) -antibody tests at the screening examination. * Drug allergy. * Bronchial asthma. * Participation in another clinical study within three month prior to the start of this study (exception: characterization of metabolizer status). * Blood donation (more than 100 milliliters) within three month prior to the start of this study. * Use of any medication within four weeks prior to the start of the study (self-medication or prescription). * Evidence of alcohol, medication or drug abuse. * Positive Naloxone challenge test. * Positive drug abuse screening test. * Extremely unbalanced diet (in the opinion of the investigator). * Excessive consumption of food or beverages containing caffeine or other xanthines (more than five cups of coffee or equivalent per day). * Smoking of more than 20 cigarettes per day. * Neurotic personality, psychiatric illness or suicide risk. * Known or suspected of not being able to comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameter: AUC48-72 for buprenorphine | From 48 hours to 72 hours | Partial area under the plasma concentration-time curve (from 48 hours after application until 72 hours after application). |
| Pharmacokinetic parameter: AUC72-96 for buprenorphine | From 72 hours to 96 hours | Partial area under the plasma concentration-time curve (from 72 hours after application until 96 hours after application). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameter: AUC0-t for buprenorphine | Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours | Area under plasma concentration-time curve from application until the last sampling point (t) with a quantifiable concentration, calculated by the linear/log trapezoidal method, i.e., the linear trapezoidal rule is applied up to Cmax and then the log trapezoidal rule is applied for the remainder of the curve. |
| Pharmacokinetic parameter: t1/2z for buprenorphine | Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours | Apparent terminal elimination half-life. |
| Pharmacokinetic parameter: AUC0-inf for buprenorphine | Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours | Area under the plasma concentration-time curve extrapolated to infinity. |
| Pharmacokinetic parameter: Cmax for buprenorphine | Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours | Maximum observed plasma concentration of the measured concentration-time profile. Blood samples will be taken for the determination of buprenorphine plasma concentrations at distinct time points: Before application to 144 hours after patch application. If the patch was applied for 96 hours, additional samples were taken at 156 and 168 hours after application. For the analysis of buprenorphine in human plasma, a validated liquid chromatography mass spectrometry (LC/MS/MS)-method will be used. |
| Characteristics of treatment emergent adverse events | From patch application (Day 1) until Final check (Day 12) | Adverse events with information on intensity, seriousness, relationship to the investigational product, outcome and action taken will be determined. |
| Onset and duration of treatment emergent adverse events | From patch application (Day 1) until Final check (Day 12) | Adverse events with information on onset and duration to the investigational product will be determined. |
| Incidence of treatment emergent adverse events | From patch application (Day 1) until Final check (Day 12) | Number of adverse events and number of participants with adverse events. |
| Pharmacokinetic parameter: tmax for buprenorphine | Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours | Time of maximum concentration, time after transdermal patch application at which Cmax occurs. |
Countries
Germany
Outcome results
None listed